Organon & Co | OGN - Gross Profit On Sales

Stock Price
6.27
Daily Change
0.04 0.64%
Monthly
-22.59%
Yearly
-59.85%
Q1 Forecast
6.16

Organon & Co reported $854M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Deva Holding AS TRY 1.32B 235.77M Sep/2023
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Merck USD 13.42B 431M Sep/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Novartis USD 10.82B 694M Sep/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Organon & Co USD 854M 3M Dec/2025
Pharma Mar EUR 86.7M 53.34M Dec/2025
Qiagen NV USD 325.27M 19.53M Dec/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 67.63M 15.62M Mar/2025